Literature DB >> 21733472

Understanding the burden of depression.

Larry Culpepper1.   

Abstract

Major depressive disorder is a highly prevalent, chronic, and disabling disease affecting millions of individuals worldwide. The burden of major depressive disorder includes impaired role functioning, decreased quality of life, the development of medical conditions, and increased morbidity and mortality. The long-term, recurrent nature of depression and its frequent resistance to available therapies lead to increased utilization of health services, which represents a large financial burden in health care costs. Major depressive disorder is often undertreated; however, even when treatment is adequate, remission rates are low and partial response is common. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21733472     DOI: 10.4088/JCP.10126tx1c

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review.

Authors:  Ilya Demchenko; Vanessa K Tassone; Sidney H Kennedy; Katharine Dunlop; Venkat Bhat
Journal:  Front Psychiatry       Date:  2022-05-26       Impact factor: 5.435

Review 2.  Nutrition, Epigenetics, and Major Depressive Disorder: Understanding the Connection.

Authors:  Miguel A Ortega; Óscar Fraile-Martínez; Cielo García-Montero; Miguel Angel Alvarez-Mon; Guillermo Lahera; Jorge Monserrat; Maria Llavero-Valero; Fernando Mora; Roberto Rodríguez-Jiménez; Sonia Fernandez-Rojo; Javier Quintero; Melchor Alvarez De Mon
Journal:  Front Nutr       Date:  2022-05-18

3.  Anomalous gray matter structural networks in major depressive disorder.

Authors:  Manpreet K Singh; Shelli R Kesler; S M Hadi Hosseini; Ryan G Kelley; Debha Amatya; J Paul Hamilton; Michael C Chen; Ian H Gotlib
Journal:  Biol Psychiatry       Date:  2013-04-18       Impact factor: 13.382

4.  Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.

Authors:  Narong Maneeton; Benchalak Maneeton; Manit Srisurapanont; Stephen D Martin
Journal:  BMC Psychiatry       Date:  2012-09-27       Impact factor: 3.630

5.  Blood BDNF level is gender specific in severe depression.

Authors:  Anatoly Kreinin; Serah Lisson; Elimelech Nesher; Jenny Schneider; Josef Bergman; Kamal Farhat; Joseph Farah; Flavio Lejbkowicz; Gal Yadid; Leon Raskin; Igor Koman; Albert Pinhasov
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

6.  Aberrant Global and Regional Topological Organization of the Fractional Anisotropy-weighted Brain Structural Networks in Major Depressive Disorder.

Authors:  Jian-Huai Chen; Zhi-Jian Yao; Jiao-Long Qin; Rui Yan; Ling-Ling Hua; Qing Lu
Journal:  Chin Med J (Engl)       Date:  2016-03-20       Impact factor: 2.628

7.  Mortality and suicide risk in treatment-resistant depression: an observational study of the long-term impact of intervention.

Authors:  Bryan Olin; Amara K Jayewardene; Mark Bunker; Francisco Moreno
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

Review 8.  Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.

Authors:  Bashkim Kadriu; Laura Musazzi; Ioline D Henter; Morgan Graves; Maurizio Popoli; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2019-02-01       Impact factor: 5.176

9.  Psychometric Properties of the Chinese Version of the Clinically Useful Depression Outcome Scale for Patients with Major Depressive Disorder.

Authors:  Hai-Yan Ma; Xue-Mei Wang; Xiao-Jie Huang; Cheng-Jia Yang; Dong-Fang Sheng; Jing-Jing Yang; Ming-Zhi Xu
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-21       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.